Without evidence that monoclonal antibody treatments being developed for low-density lipoprotein reduce cardiovascular illness and not just cholesterol numbers, pharmacy benefit managers and payers may be reluctant to cover the drugs, Edward C. Lawrence writes. These new biologic drugs' prices could add weight to the push for a pathway for the development of biosimilars.

Full Story:
RxObserver blog

Related Summaries